International clinical studies
Due to its results, our department has been selected as a Centre for conducting international clinical trials. This is a recognition of the high standard of our cardiology outpatient clinic and at the same time it allows us to administer to our patients the latest drugs unavailable in standard medical facilities. For example, we have participated and are participating in the following studies
Maritime CV - an international study with cafraglutide, the only substance that should effectively reduce weight and the incidence of vascular events when dosed once a month.
The GZBO Study, an investigational drug retatrutide, aims to reduce cardiovascular and renal adverse events. Our cardiology center is among the most active centers in the country, M.D. Wiendl is the National Leader for this study for the Czech Republic.
BaxDuo Prevent HF - an international study testing new substance baxdrostat, the aim is reducing the incidence of vascular events and heart failure at high and very high risk patients. We are the first open centre of this study in the Czech Republic.
Victorion Prevent – sponsored by Novartis. Our facility is the first center in the Czech Republic to open, and we are one of the few in the country participating in the study.
The project is investigating the use of the latest cholesterol-lowering drug, inclisiran, which only needs to be administered subcutaneously twice a year and has a significantly greater effect than the cholesterol-lowering tablets currently in use. We are enrolling patients at high risk of cardiovascular events in the study, where currently available treatments have not led to a sufficient reduction in cholesterol levels.
HORIZON - sponsored by Novartis. This is an international, multicenter, randomized Phase 3 clinical trial evaluating the effect of pellacarsen on protection against the development of vascular complications such as myocardial infarction, stroke. This drug effectively reduces the level of lipoprotein (a), part of the so-called harmful cholesterol. Lipoprotein (a) is a very harmful particle for the blood vessels and a causal link is thought to exist between the occurrence of heart attacks and elevated levels of lipoprotein (a) in people without other risk factors. We do not yet have a specific treatment to reduce this lipoprotein, so the outcome of this study is eagerly awaited by the professional community.
AZURE-LDL - a study in patients at high and very high cardiovascular risk, testing the effect of an oral PCSK9 inhibitor in preventing the onset of cardiovascular disease.
Move-Lp(a) study - a study in patients with high and very high vascular risk, testing an oral drug that lowers lipoprotein levels, a very risky parameter for vascular disease.